TLRY — Tilray Brands, Inc.

Tilray Brands (TLRY) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: $206.7 million, an 11% increase year-over-year.
• Gross Profit: $55 million, up 6% year-over-year, with a gross margin of 27%.
• Net Loss: $25.2 million, significantly improved from a loss of $793.5 million in the prior year.
• Adjusted EBITDA: $10.7 million, a 19% increase year-over-year.
• Cash Position: Ended the quarter with $264.8 million in cash and marketable securities, with a net cash position of $3.5 million.

2. Strategic Updates and Business Highlights:

• International Cannabis Growth: Achieved $24.1 million in international cannabis sales, a 73% year-over-year increase, driven by strong performance in Germany and other markets.
• Distribution Business: Revenue grew 35% year-over-year to $83 million, benefiting from portfolio optimization and increased medical device sales.
• Beverage Business: Revenue was $42.6 million, impacted by margin-focused actions and industry softness, but operational fundamentals are improving.
• BrewDog Acquisition: Acquired BrewDog for approximately EUR 40 million, enhancing Tilray's craft beverage platform and expected to generate $500 million in global craft beverage revenue.
• Partnership with Carlsberg: Set to begin in January 2027, aimed at expanding distribution and leveraging Carlsberg’s expertise.

3. Forward Guidance and Outlook:

• Adjusted EBITDA Guidance: Reaffirmed for fiscal 2026 at $62 million to $72 million.
• International Expansion: Positioned to capitalize on evolving regulatory environments, particularly in the U.S. and Europe, with a focus on consistent supply and product quality.
• Beverage Segment Improvement: Expected to see improved margins as cost structures stabilize and new partnerships take effect.

4. Bad News, Challenges, or Points of Concern:

• Price Compression: Ongoing price pressures in international markets, particularly affecting gross margins.
• Operational Challenges: Integration of BrewDog and managing the complexities of multiple acquisitions may pose risks.
• Regulatory Risks: Potential changes in U.S. cannabis regulations, particularly concerning hemp-derived THC products, could impact future sales.
• Beverage Margin Pressures: Beverage gross margins decreased to 32%, affected by higher input costs and lower overhead absorption rates.

5. Notable Q&A Insights:

• Balancing International and Canadian Markets: Management emphasized the importance of maintaining supply for international markets while stabilizing Canadian operations, highlighting recent improvements in yield and production capabilities.
• Project 420 Completion: The completion of cost-saving initiatives does not signal an end to efficiency efforts; ongoing projects are expected to continue.
• Route to Market in Germany: The company is focusing on a direct-to-pharmacy model, leveraging CC Pharma's extensive network to enhance distribution.
• BrewDog Integration: Management acknowledged the challenges of integrating BrewDog but expressed optimism about the brand's potential and the strategic advantages it brings.
• Hedging Strategies: The company is actively hedging aluminum costs, covering 65% to 75% of purchases, which is expected to mitigate some margin pressures.

Overall, Tilray Brands reported strong growth in key areas, particularly international cannabis and distribution, while navigating challenges in the beverage segment and regulatory landscape. The company remains focused on strategic partnerships and operational efficiencies to drive future growth.